Dual Promoter Lentivirus Vector Enrichment for Lysosomal Storage Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating lysosomal storage disorders like Fabry disease and Gaucher disease, such as enzyme replacement therapy, have limitations including low systemic expression of therapeutic enzymes and high treatment costs.
Innovation Solution
A dual promoter lentivirus vector is used to express a protein of interest, such as α-galactosidase A or beta-glucocerebrosidase, along with IMPDH2(IY), which confers resistance to mycophenolic acid, allowing for selective enrichment of transduced hematopoietic cells in vivo using mycophenolate mofetil.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat lysosomal storage disorders, then patients can receive therapeutic enzyme supplementation, but treatment costs are extremely high and require lengthy intravenous infusions every few weeks
Solution Approach 1:
The patent applies preliminary action by genetically modifying hematopoietic stem cells ex vivo before transplantation. The stem cells are transduced with lentiviral vectors containing the therapeutic gene (e.g., α-galactosidase A for Fabry disease) and selective markers (e.g., IMPDH2 conferring mycophenolic acid resistance) before being reinfused into the patient. This preliminary genetic modification enables long-term endogenous enzyme production, eliminating the need for repeated intravenous enzyme infusions.
2Quantity of substance
If hematopoietic stem cells are transduced with lentiviral vectors to produce therapeutic enzymes, then systemic enzyme levels can be increased, but the number of transduced cells expressing the therapeutic enzyme remains relatively low
Solution Approach 1:
The patent implements feedback control through selective enrichment. After stem cell transplantation, patients receive mycophenolic acid (or mycophenolate mofetil) that selectively kills non-transduced cells lacking the IMPDH2 resistance marker. This creates a feedback mechanism where the therapeutic transduced cells are selectively preserved and expanded, while non-transduced cells are eliminated. The selective pressure continuously enriches the transduced cell population, increasing systemic enzyme levels over time.
3Reliability
If the number of transduced hematopoietic cells is increased to improve systemic enzyme levels, then treatment efficacy can be enhanced, but treatment costs increase
Solution Approach 1:
The patent applies self-service by enabling the transduced hematopoietic stem cells to self-enrich and self-sustain the therapeutic enzyme production. The selective marker system allows the transduced cells to automatically outcompete and replace non-transduced cells through selective survival advantage in the presence of mycophenolic acid. This self-enrichment process continuously increases the proportion of therapeutic cell production without requiring additional external interventions or increasing treatment costs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the number of circulating cells expressing the therapeutic enzyme, leading to improved treatment efficacy and reduced treatment costs by enhancing systemic enzyme levels and minimizing toxicity.
Implementation Method 1
transducing the cells with a recombinant lentivirus vector carrying the transgene
Implementation Method 2
IMPDH2(IY), which confers resistance to mycophenolic acid, allowing for selective enrichment of transduced hematopoietic cells in vivo using mycophenolate mofetil
Data Source
AI summary
The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.